<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; PMO</title>
	<atom:link href="http://www.stockbloghub.com/tag/pmo/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AMGN) Amgen&#8217;s Pipline Candidate Prolia Earns FDA Approval in U.S.</title>
		<link>http://www.stockbloghub.com/2010/06/03/amgn-amgens-pipline-candidate-prolia-earns-fda-approval-in-u-s/39180</link>
		<comments>http://www.stockbloghub.com/2010/06/03/amgn-amgens-pipline-candidate-prolia-earns-fda-approval-in-u-s/39180#comments</comments>
		<pubDate>Thu, 03 Jun 2010 13:14:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[Putnam Municipal Opportunities Trust]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=39180</guid>
		<description><![CDATA[Amgen Inc. (AMGN) is on a roll with its key pipeline candidate, Prolia, receiving back to back approval in both the EU and the US. While Prolia gained approval in the EU for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures, the US Food and Drug Administration (FDA) approved the product for the treatment of osteoporosis in postmenopausal women at increased risk of fractures or patients who have failed or are intolerant to other osteoporosis treatments. The FDA approval, which came more than a month before the action date of July 25, is a major boost for Amgen. Prolia has been competitively priced at $825 per ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/03/amgn-amgens-pipline-candidate-prolia-earns-fda-approval-in-u-s/39180/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

